Drimva

AstraZeneca

Senior Scientist, Allogeneic T-Cell Therapy Process Development

$112K–$168K

US - Gaithersburg - MD · Senior · Full-time · Posted Oct 27, 2026

Experience
BS with >6 years of relevant experience, or MS with a minimum of 4 years, or PhD with a minimum of 1 year of relevant proven experience.
Education
BS in Biochemical Engineering, Biomedical Engineering, Biotechnology, or related field; or MS; or PhD.

About the job

Develops, optimizes, characterizes, and scales manufacturing processes for allogeneic CAR-T and TCR-T cell therapies, supporting clinical manufacturing and technology transfer.

What you'll do

  • Design, execute, analyze, interpret, and document process development studies, including hands-on T-cell culture, gene editing, expansion, scale-up, and characterization.
  • Support technology transfer and clinical manufacturing readiness through documentation, troubleshooting, deviation investigations, change control, process monitoring, and risk assessments.
  • Collaborate across functions and mentor junior scientists; contribute to development reports, publications, patents, and regulatory filings.

What they ask for

  • Human primary-cell culture, including T-cell culture, and strong flow cytometry/T-cell characterization experience.
  • Cell engineering in scale-up processes using manufacturing-ready genome-editing tools and DNA/RNA transfection approaches.
  • Knowledge of upstream and downstream cell-therapy process development, including laboratory work and technology transfer.
  • Fundamentals of DOE, strong experimental design and data analysis, troubleshooting, teamwork, communication, and technical writing skills.

Nice to have

  • Immunology; CRISPR/Cas9, base editing, or viral transduction experience; GMP experience.
  • Cell characterization experience with dPCR, ELISA, or NGS.

Pay

$112,304.00 - $168,456.00 USD (base salary)

Tools

CAR-T, TCR-T, flow cytometry, DOE, CRISPR/Cas9, base editing, DNA/RNA transfection, dPCR

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 5, 2026 (UTC)